Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children

Clinical Infectious Diseases

Volumn 36, Issue 11, 2003, Pages 1476-1482

  Gatti, Giorgio ^a,d,e   Castelli Gattinara, G ^b   Cruciani, M ^c   Bernardi, S ^b   De Pascalis, C R ^a   Pontali, E ^a   Papa, L ^a   Miletich, F ^a   Bassetti, D ^a  

^a G GASLINI INSTITUTE   (Italy)

^b Bambin Gesù Pediatric Cardiology Hospital   (Italy)

^c Center of Preventive Medicine   (Italy)

^d VERTEX PHARMACEUTICALS   (United States)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AGE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; NELFINAVIR;

EID: 0038806658     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375062     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Recomm Rep 1998; 47:1-43.
2. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000; 59:581-620.
3. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999; 341:1874-81.
4. Wizna A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial - PACTG 377. AIDS Res Hum Retroviruses 2000; 16:1113-21.
5. Nadal D, Steiner F, Cheseaux JJ, et al. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Infection 2000; 28:287-96.
6. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28:1109-18.
7. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 1999; 13:1653-8.
8. Gibb DM, Newberry A, Klein N, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000; 355:1331-2.
9. Quart BD, Chapman SK, Peterskin J, et al. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 - a novel HIV protease inhibitor [abstract LB3]. In: Proceedings of the 2nd National Conference on Human Retroviruses and Opportunistic Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995:167.
10. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol 1998; 38:736-43.
11. Schuster T, Linde R, Wintergerst U, et al. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing. AIDS 2000; 14:1466-8.
12. Hayashi S, Wiznia A, Jaywardene A, et al. Nelfinavir pharmacokinetics in stable HIV positive children: the effect of weight and a comparison of BID to TID dosing [abstract 427]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999:148.
13. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J 2001; 20:746-51.
14. Centers for Disease Control and Prevention. Guidelines for the use of amiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998; 47:1-43.
15. Molla A, Vasavanoda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250:255-62.
16. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 2000; 182:758-65.
17. Baede-van Dijk PA, Hugen PWH, Verweij-van Wissen CPWGM, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001; 15:991-8.
18. Marzolini C, Buclin T, Decosterd LA, et al. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 2001; 23:394-8.
19. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15(Suppl 5):S171-81.
20. Malaty L, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Safety 1999; 20:147-69.
21. Bergshoeff AS, Fraaij P, Wolfs T, et al. Nelfinavir pharmacokinetics in HIV infected children: who are at risk for subtherapeutic plasma levels [abstract TuPeB4557]? In: Program and abstracts of the 14th International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002:14.